1774893-22-9

Basic information

• Product Name: 6-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid
• CAS NO: 1774893-22-9
• Molecular Weight: 234.178
• Mol File: 1774893-22-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 412.3±40.0 °C(Predicted)
• Density: 1.61±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 6-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid(1774893-22-9)
• EPA Substance Registry System: 6-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-2-carboxylic acid(1774893-22-9)

Safety Data

• Hazardous Substances Data: 1774893-22-9(Hazardous Substances Data)

Upstream product

• 860457-99-4 ethyl 6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylate 
• 74784-70-6 2-amino-5-trifluoromethylpyridine 

Relevant articles and documents

PRMT5 INHIBITORS

The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

NOVEL PHARMACEUTICAL COMPRISING HETEROAROMATIC AMIDE DERIVATIVE OR SALT THEREOF

PROBLEM TO BE SOLVED: To provide a compound useful for treating or preventing disease associated with voltage-dependent sodium channel (Nav1.7) such as disease involving a pain, disease involving an itch, autonomic nerve-associated disease, or a pharmaceutical composition thereof. SOLUTION: The present disclosure provides a compound illustrated by the following formula, and a pharmaceutical composition containing the same. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT